EUVIMEDEUVIMED entdecken
Crossref

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells

Ivan J Cohen iD, Audrey C Bochi-Layec iD, Jean Lemoine iD, Scott Jenks iD, Pedram Bayat iD, Ki Hyun Kim iD, Huiwu Zhao iD, Ositadimma Ugwuanyi, Federico Stella iD, Guido Ghilardi iD, Giulia Gabrielli iD, Sarah McCuaig iD und 39 weitere

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.adr9382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Ivan J Cohen und 50 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Receptors, Antigen, B-Cell, B-Lymphocytes, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current US Food and Drug Administration–approved chimeric antigen receptor (CAR) T cell therapies for B cell leukemias and lymphomas target CD19, which is widely expressed across the B cell lineage, often leading to on-target, off-tumor B cell depletion, prolonged immune suppression, and antigen-negative escape in a subset of patients. In contrast, B cell receptor (BcR) signaling is essential for the survival of most mature B cell neoplasms, and BcRs carrying the immunoglobulin heavy variable gene IGHV4-34 are highly enriched in B cell malignancies compared with normal B cells. Further, self-reactive IGHV4-34 + serum autoantibodies are enriched in aggressive systemic lupus erythematosus (SLE) and other autoimmune diseases. Here, we developed CAR T cells targeting the BcR carrying IGHV4-34 (CART4-34). We found that CART4-34 showed specific cytotoxicity and cytokine secretion toward IGHV4-34 + malignant B cells. In addition, although CD19 was down-regulated upon relapse after treatment with CART19, IGHV4-34 + BcR levels remained intact upon relapse after treatment with CART4-34, suggesting reduced risk of antigen-negative escape. In IGHV4-34 + HBL1 cell line–derived xenograft mouse models, CART4-34 showed robust expansion and antitumor activity comparable to those of CART19. Optimized CAR:BcR binding using shorter CAR hinge domains improved immune synapse morphology and in vivo activity. In addition, we showed that CART4-34 could target human IGHV4-34 + SLE B cells and deplete IGHV4-34 + autoantibodies ex vivo, without targeting healthy B cells or affecting total IgG titers. In conclusion, we developed a CAR T cell product that specifically targets pathogenic B cells in lymphoid malignancies and SLE, offering potential for precision cell therapy for these indications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Antigen, B-CellB-LymphocytesReceptors, Chimeric AntigenT-LymphocytesImmunoglobulin Heavy ChainsAutoimmunityHumansAnimalsMiceAntigens, CD19Cell Line, Tumor

Substanzen

Receptors, Antigen, B-CellReceptors, Chimeric AntigenAntigens, CD19Immunoglobulin Heavy Chains

Autor:innen und Institutionen

  • Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Medicine, Division of Hematology/Oncology, Hospital of University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Medicine, Division of Rheumatology, School of Medicine, Lowance Center for Human Immunology, Emory University, Atlanta, GA 30322, USA.
  • Department of Surgery, Hospital of University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

ORCID-Profile: Ivan J Cohen, Audrey C Bochi-Layec, Jean Lemoine, Scott Jenks, Pedram Bayat, Ki Hyun Kim, Huiwu Zhao, Federico Stella, Guido Ghilardi, Giulia Gabrielli, Sarah McCuaig, Maria Karipidou, Eleni Bouziani, David Espie, Andreas Agathangelidis, Aditya Bhosale, Luca Paruzzo, Giovanni Medico, Regina Bugrovsky, Puneeth Guruprasad, Li-Ping Wang, Jaryse Harris, Evgeny Arons, Yunlin Zhang, Raymone Pajarillo, Chi-Ping Day, S Cenk Sahinalp, Bria Fulmer, Marcos Cases, Patrizia Porazzi, E John Wherry, Robert J Kreitman, Sokratis A Apostolidis, Edward M Behrens, Vijay Bhoj, Ignacio Sanz, Stephen J Schuster, Paolo Ghia, Kostas Stamatopoulos, Marco Ruella

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NIAID NIH HHS
  • Lymphoma Research Foundation
  • Hairy Cell Leukemia Research Foundation
  • Leukemia and Lymphoma Society
  • Frederick National Laboratory for Cancer Research
  • Center for High Performance Computing, Shanghai Jiao Tong University

Zitieren

APA

Cohen, I. J., Bochi-Layec, A. C., Lemoine, J., Jenks, S., Bayat, P., Kim, K. H., Zhao, H., Ugwuanyi, O., Stella, F., Ghilardi, G., Gabrielli, G., McCuaig, S., Iatrou, A., Vlachonikola, E., Karipidou, M., Bouziani, E., Espie, D., Ramasubramanian, R., Agathangelidis, A., …, & Ruella, M. (2026). Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adr9382

Vancouver

Cohen IJ, Bochi-Layec AC, Lemoine J, Jenks S, Bayat P, Kim KH, et al. Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.adr9382

BibTeX
@article{Cohen2026,
  author = {Cohen, Ivan J and Bochi-Layec, Audrey C and Lemoine, Jean and Jenks, Scott and Bayat, Pedram and Kim, Ki Hyun and Zhao, Huiwu and Ugwuanyi, Ositadimma and Stella, Federico and Ghilardi, Guido and Gabrielli, Giulia and McCuaig, Sarah and Iatrou, Anastasia and Vlachonikola, Elisavet and Karipidou, Maria and Bouziani, Eleni and Espie, David and Ramasubramanian, Ranjani and Agathangelidis, Andreas and Bhosale, Aditya and Paruzzo, Luca and Medico, Giovanni and Kolar, Bronte and Bugrovsky, Regina and Guruprasad, Puneeth and Wang, Li-Ping and Harris, Jaryse and Arons, Evgeny and Zhang, Yunlin and Pajarillo, Raymone and Kreiger, Portia A and Day, Chi-Ping and Sahinalp, S Cenk and Wu, Chih Hao and Santi, Alessia and Fulmer, Bria and Cases, Marcos and Palmer, Matthew B and Porazzi, Patrizia and Wherry, E John and Kreitman, Robert J and Tiacci, Enrico and Apostolidis, Sokratis A and Behrens, Edward M and Bhoj, Vijay and Sanz, Ignacio and Inghirami, Giorgio and Schuster, Stephen J and Ghia, Paolo and Stamatopoulos, Kostas and Ruella, Marco},
  title = {Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.adr9382}
}
Kostenlos starten →